UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020573
Receipt number R000023753
Scientific Title Effect of monosodium glutamate on cognitive function in people with dementia
Date of disclosure of the study information 2016/01/15
Last modified on 2016/01/19 17:06:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of monosodium glutamate on cognitive function in people with dementia

Acronym

Effect of monosodium glutamate on cognitive function in people with dementia

Scientific Title

Effect of monosodium glutamate on cognitive function in people with dementia

Scientific Title:Acronym

Effect of monosodium glutamate on cognitive function in people with dementia

Region

Japan


Condition

Condition

dementia

Classification by specialty

Neurology Geriatrics Psychiatry

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate that monosodium glutamate affect on cognitive function in people with dementia.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The result of Touch panel-type Dementia Assessment Scale (TDAS) just after intervention.

Key secondary outcomes

The results of Gottfries, Brane and Steen scale (GBSS), questionnaire and blood tests just after intervention.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

Subjects take a meal with 0.9g monosodium glutamate three times a day (breakfast, lunch and dinner) for three months. We perform tests three times (before intervention, after intervention and one month after the intervention period).

Interventions/Control_2

Subjects take a meal with 0.28g NaCl three times a day (breakfast, lunch and dinner) for three months. We perform tests three times (before intervention, after intervention and one month after the intervention period).

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Subjects with dementia
2) Subjects that informed consent was provided from the person and the relative

Key exclusion criteria

1) Subjects who are diagnosed taste disturbance
2) Subjects who received chemotherapy within the past one year
3) Subjects who have been performed the dietary therapy for hypertension such as sodium restriction
4) Subjects who are assessed by the principal investigator due to other reasons

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Katsuya Urakami

Organization

School of Health Science, Faculty of Medicine, Tottori University

Division name

Department of Biological Regulation

Zip code


Address

86 Nishicho, Yonago, Tottori, Japan

TEL

0859-38-6354

Email

kurakami@med.tottori-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Minoru Kouzuki

Organization

School of Health Science, Faculty of Medicine, Tottori University

Division name

Department of Biological Regulation

Zip code


Address

86 Nishicho, Yonago, Tottori, Japan

TEL

0859-38-6358

Homepage URL


Email

kouzuki@med.tottori-u.ac.jp


Sponsor or person

Institute

Department of Biological Regulation, School of Health Science, Faculty of Medicine, Tottori University

Institute

Department

Personal name



Funding Source

Organization

Ajinomoto Co., Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 01 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2014 Year 02 Month 01 Day

Date of IRB


Anticipated trial start date

2014 Year 09 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 01 Month 14 Day

Last modified on

2016 Year 01 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023753


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name